Cantor Fitzgerald Estimates FDMT FY2026 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of 4D Molecular Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($2.86) per share for the year. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02).

Other equities research analysts have also issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. The Goldman Sachs Group reduced their price objective on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Weiss Ratings restated a “sell (e+)” rating on shares of 4D Molecular Therapeutics in a research report on Saturday, May 24th. Chardan Capital dropped their target price on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a “buy” rating for the company in a report on Friday, May 9th. Finally, Royal Bank of Canada cut their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $29.56.

4D Molecular Therapeutics Stock Down 6.7%

NASDAQ FDMT opened at $4.47 on Wednesday. 4D Molecular Therapeutics has a 52 week low of $2.24 and a 52 week high of $28.93. The company has a market capitalization of $207.07 million, a P/E ratio of -1.57 and a beta of 2.84. The stock’s 50-day moving average price is $3.34 and its 200-day moving average price is $4.58.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of FDMT. BVF Inc. IL boosted its holdings in shares of 4D Molecular Therapeutics by 70.8% during the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company’s stock valued at $14,733,000 after purchasing an additional 1,890,647 shares during the last quarter. Millennium Management LLC lifted its position in shares of 4D Molecular Therapeutics by 1,607.1% in the fourth quarter. Millennium Management LLC now owns 1,420,723 shares of the company’s stock worth $7,913,000 after buying an additional 1,337,497 shares in the last quarter. Federated Hermes Inc. boosted its stake in 4D Molecular Therapeutics by 33,131.8% during the first quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company’s stock valued at $4,038,000 after buying an additional 1,246,419 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in 4D Molecular Therapeutics by 159.5% during the fourth quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company’s stock valued at $4,568,000 after buying an additional 504,086 shares during the last quarter. Finally, Norges Bank purchased a new position in 4D Molecular Therapeutics during the 4th quarter valued at approximately $2,790,000. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.